3Yashima K,Litzky LA,Kaiser L,et al. Telomerase expression in respiratoy epithelium during the multistage pathogenesis of lung crcinomas. Cancer Res. 1997,57: 2373-2377.
7Gohji K, Fujimoto N, Serum matrix metalloproteinase-2 and densily in men with prostate cancer as a new predictor of disease extentsion, Int J Cancer. 1998,79(11):96-101.
8Hasturk S. Kemp B. Kalapurakai SK. et al. Expression of clooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and non-small cell lung carcinoma, Cancer,2002,94(4): 1023-1031.
10Fadlo RK, Hong WJ, Jack L, et al. cyclooxygenase-2 Overexpression is a marker of poor prognosis in stage 1 non-small cell lung cancer. Clin Carcer Res,2001,7(2):861-867.
二级参考文献30
1Still K,Robson CN,Autzen P,et al.Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase 2(TIMP-2) in human benign and malignant protatic tissue.Prostate,2000,42 (2):18-25.
2Gohji K,Fujimoto N.Serum matrix metalloproteinase-2 and density in men with prostate cancer as a new predictor of disease extension.Int J Cancer,1998,79 (11):96-101.
3Arii S,Mise M,Harada T,et al.Overexpression of matrix metalloproteinase-9 gene in hepatocellular carcinoma with invasive potential.Hapatolog,1996,24(2):316-319.
4Okazaki L,Wada N,Nakano M,et al.Difference in gene expression for matrix metalloproteinase-1 between early and hepatocellular carcinomas.Hepatol,1997,25(3):580-584.
5Hayasaka A,Suzuki N,Fujimoto N,et al.Elevated plasma levels of matrix metalloproteinase-9(92kd type collagenase / gelatinase B ) in hepatocellular carcinoma.Hepatol,1996,24 (5):1058-1062.
6Nakatsukasa H,Ashida K,Higashi T,et al.Cellular distribution of transcripts for tissue inhibitor of metalloproteinase -1 and 2 in human hepatocellular carcinomas.Hepatol,1996,24 (1):82-86.
7Hanemaaier R,Verheijen JH,Mayuire YM,et al.Increased gelatinase A and gelatinase-B activities in mallignant vs benign breast tumors.Int Cancer,2000,86,204-207.
8Cawston T.Matrix metalloproteinases and TIMPs properties and implications for the rheumatic disease.Mol Med Today,1998,4(2):130-135.
9Mitsiades N,Yu WH,Poulaki V,et al.Matrix metalloproteinase -7 mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity.Cancer Res,2001,61(2):577-581.
10Boulay A,Masson R,Chenard MP,et al.High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase.Cancer Res,2001,61(5):2189-2193.
